Exhibits leukotriene-A4 hydrolase activity. Involved in several processes, including leukotriene metabolic process; response to zinc ion; and type I pneumocyte differentiation. Localizes to cytoplasm and nucleus. Biomarker of adenocarcinoma; asthma; and squamous cell carcinoma. Orthologous to human LTA4H (leukotriene A4 hydrolase); PARTICIPATES IN acetylsalicylic acid pharmacodynamics pathway; antipyrine drug pathway; arachidonic acid metabolic pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 2,6-dinitrotoluene; 4,4'-diaminodiphenylmethane.
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of LTA4H mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of LTA4H mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of LTA4H mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of LTA4H mRNA
cyclohexene inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4], cyclohexene inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
Oxygen inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4], Oxygen inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LTA4H mRNA
1-4-benzothiazol-2-yloxybenzylpiperidine-4-carboxylic acid inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4] more ...
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LTA4H mRNA
Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4], Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
propanethiol inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4], propanethiol inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LTA4H mRNA
[Zinc deficiency inhibits the reaction [PTGS2 gene mutant form results in decreased susceptibility to nitrosobenzylmethylamine]] which results in increased expression of LTA4H protein
[Zinc deficiency inhibits the reaction [PTGS2 gene mutant form results in decreased susceptibility to nitrosobenzylmethylamine]] which results in increased expression of LTA4H protein
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin